Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $32.5352W HIGH $57.81
Volume
1.26 M
Value Traded
130.50 M
Short % Float
3.74%
-0.9%Week
+7.71%1 Month
+9.51%3 Month
+8.28%6 Month
-35.02%5 Year
+1,504.93%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
9.35 B
EPS (TTM)
1.95
P/E Ratio
23.27
Ent. Value
8.25 B
Total Shares
206.01 M
Float Shares
204.83 M
Insiders
0.60%
Institutions
77.98%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
QGEN Catalyst Timeline
Dated clinical, regulatory and corporate events for Qiagen N.V.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Qiagen N.V.
399Total events
10Upcoming
104Tier-1 (high impact)
2005 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲FDA ApprovalFDA Decision
FDA clearance of QIAstat-Dx BCID GN Plus AMR Panel for gram-negative bloodstream infections
bloodstream infections (gram-negative bacteria and antibiotic resistance markers)source ↗
▲Product LaunchQIAminiPost-Market
QIAGEN launches QIAmini compact automated sample preparation system
●Management ChangeCorporate
Thierry Bernard stepped down as Chief Executive Officer and Managing Board member
▲FDA ApprovalFDA Decision
FDA cleared QIAstat-Dx BCID GPF Plus AMR Panel
bloodstream infectionssource ↗
▲Product LaunchPost-Market
Launch of CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe
bloodstream infectionsource ↗
◆Product LaunchPost-Market
QIAsymphony Connect full IVDR commercialization targeted for mid-2026
▲Product LaunchPost-Market
Global launch of QIA Agent, an AI-powered digital assistant for researchers
▲Partnership / LicenseCorporate
Automation partnership with Inpeco for QuantiFERON IGRA testing
◆Oral PresentationQuantiFERONPresentation
QuantiFERON Spotlight Session on strategic priorities and latest update
latent TBsource ↗
◆Oral PresentationPresentation
QIAGEN to present new Sample to Insight solutions at AACR 2026
oncologysource ↗
▲Product LaunchPost-Market
Launch of CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel
bloodstream infectionssource ↗
▲Product LaunchQIAstat-DxFiledPost-Market
Launch of QIAstat-Dx panel for bloodstream infection syndromic testing
bloodstream infectionsource ↗
▲PublicationPresentation
Study published in BMC Public Health evaluating QFT-Plus in HIV patients in Thailand
tuberculosissource ↗
▲Quarterly UpdateCorporate
QIAGEN reports Q4 2025 net sales of $540 million, exceeding outlook
▲Product LaunchPost-Market
Launch of LIAISON QuantiFERON-TB Gold Plus II in the U.S.
tuberculosis infection detectionsource ↗
▲Product LaunchPost-Market
Launch of QuantiFERON-TB Gold Plus II in the US
latent tuberculosissource ↗
▼Equity OfferingCorporate
Completion of synthetic share repurchase of approximately $500 million
▲Product LaunchPost-Market
QIAsprint Connect launched for high-throughput research sample processing
▲Product LaunchPost-Market
QIAsymphony Connect launched for medium-throughput research and clinical sample processing
▼Equity OfferingCorporate
QIAGEN completes $500 million synthetic share repurchase in January 2026
▲Product LaunchQIAcuityPost-Market
QIAcuity reaches over 3,200 cumulative placements since launch
▲Product LaunchQIAstat-DxFiledPost-Market
QIAstat-Dx cumulative placements surpass 5,200 at year-end 2025
▲Product LaunchPost-Market
Launch of LIAISON QuantiFERON-TB Gold Plus II in Europe and CE-mark countries
tuberculosis infection detectionsource ↗
▲Product LaunchPost-Market
Launch of QuantiFERON-TB Gold Plus II in Europe and other CE-mark countries
latent tuberculosissource ↗
▼Equity OfferingCorporate
Launch of non-US offering of net share settled convertible bonds due 2032
Past FDA Catalysts and PDUFA Decisions
How QGEN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Qiagen N.V. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every QGEN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in QGEN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 2.1 % | 20.02 M | 500.00 K | 1.14% ( 5.65 K) |
QGEN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How QGEN ranks across every disease it competes in
Competitive Position is a premium feature
See how QGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialQGEN News
QGEN▲ +1.9%today
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
QIAGEN N.V. has announced the expansion of its artificial intelligence capabilities aimed at enhancing the analysis of complex biological and genomic data. The new tools include IPA Investigator, which serves as an AI research companion for the QIAGEN Ingenuity Pathway Analysis, and the QIAGEN Discovery Platform, designed to extend these advanced capabilities further.
Read more →QGENQIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
QIAGEN N.V. has announced the FDA clearance of a new bacteria detection panel for its QIAstat-Dx bloodstream infection portfolio. This new panel allows U.S. laboratories to detect gram-negative bacteria and antibiotic resistance markers in approximately one hour. It complements an earlier FDA-cleared panel for gram-positive bacteria and fungi, enhancing the company's diagnostic capabilities.
Read more →QGENQIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
QIAGEN N.V. has launched QIAmini, an automated sample preparation system aimed at research laboratories. This compact system provides a time-saving and cost-effective solution for processing small sample batches, primarily targeting academic institutions. The introduction of QIAmini is expected to enhance efficiency in laboratories that do not require larger automation systems.
Read more →QGENQIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
QIAGEN N.V. has scheduled an Extraordinary General Meeting for November 6, 2026, to vote on the appointment of Jonathan M. Pratt to its Managing Board. Pratt, who joined as CEO on September 1, 2026, will potentially join CFO Roland Sackers on the board. This meeting highlights QIAGEN's commitment to shareholder involvement.
Read more →QGENQIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
QIAGEN has launched QIAsymphony Connect, an IVD-compliant platform designed for automated clinical nucleic acid extraction. This new platform aims to standardize extraction processes across various assay workflows in clinical laboratories. Leveraging the success of the existing QIAsymphony platform, it promises to enhance efficiency and reliability in nucleic acid extraction.
Read more →QGENQIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
QIAGEN N.V. has appointed Jonathan M. Pratt as the new Chief Executive Officer, effective September 1, 2026. Pratt brings over 25 years of international experience in life sciences, laboratory technologies, and healthcare. His previous role was as President and CEO of Filtration Group, where he successfully led the company through a significant sale.
Read more →QGENQIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden
QIAGEN N.V. has appointed Jonathan M. Pratt as the new CEO, effective September 1, 2026. Pratt has over 25 years of international leadership experience in life sciences, laboratory technologies, and healthcare. His previous role was as President and CEO of the Filtration Group, where he successfully led the company.
Read more →QGENQIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
QIAGEN has received FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, marking the first panel designed for bloodstream infections. This approval broadens QIAGEN's offerings in the syndromic testing market, now covering four major infectious disease areas. The panel aims to enhance diagnostic capabilities in critical infection management.
Read more →QGENQIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
QIAGEN N.V. reported its Q2 2026 results, showcasing net sales of $535 million, which surpassed expectations. The company maintained profitability and achieved a 5% growth in its key growth pillars. Despite a forecasted decline, QIAGEN's performance remained stable, leading to a reaffirmation of its full-year outlook.
Read more →QGENQIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
QIAGEN N.V. has emphasized its molecular testing solutions that aid in the public health response to the rising cases of cyclosporiasis in the U.S. Since May, over 1,600 confirmed cases have been reported, with an additional 7,000 potential cases under investigation. The company is collaborating with health authorities to tackle the outbreaks effectively.
Read more →QGENQIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
QIAGEN N.V. has announced the release of its second quarter 2026 financial results, scheduled for August 5, 2026. A conference call will follow on August 6, allowing stakeholders to discuss the results. This event highlights QIAGEN's commitment to transparency and investor relations.
Read more →QGENQIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe
QIAGEN N.V. has launched the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe, enhancing its bloodstream infection testing capabilities. This new panel can detect 13 gram-negative bacterial pathogens and 18 antimicrobial resistance markers from positive blood cultures within approximately one hour. This expansion aims to improve diagnostic efficiency in clinical settings.
Read more →QGENQIAGEN erweitert QIAstat-Dx-Testmenü für die Diagnostik von Blutstrominfektionen in Europa
QIAGEN has launched the CE-IVDR certified QIAstat-Dx BCID GN Plus AMR Panel in Europe. This new diagnostic tool enhances the QIAstat-Dx platform's capabilities for detecting bloodstream infections. It targets 13 gram-negative bacterial pathogens and includes 18 antimicrobial resistance markers, providing comprehensive diagnostic options for healthcare providers.
Read more →QGENQIAGEN erweitert sein QIAcuity-Portfolio für Genexpressionsanalysen und treibt so den Einsatz der digitalen PCR in Forschung und Biopharma weiter voran
QIAGEN is expanding its QIAcuity portfolio for gene expression analysis, enhancing the application of digital PCR in research and biopharma. This move indicates a strategic effort to advance technological capabilities in the field. The expansion aims to meet growing demands in gene expression studies.
Read more →QGENQIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
QIAGEN has announced an expansion of its QIAcuity gene expression portfolio. This initiative is designed to enhance the adoption of digital PCR technologies within the research and biopharma industries. The company's efforts reflect a commitment to advancing molecular diagnostics and supporting scientific innovation.
Read more →QGENQIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
QIAGEN is involved in supporting research and surveillance efforts related to the Bundibugyo Ebolavirus outbreak. The company's contributions aim to enhance the understanding and management of this infectious disease. Further details on specific initiatives or collaborations were not provided in the article.
Read more →QGENQIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
QIAGEN has launched the QIA Agent, an innovative tool designed to provide AI-driven scientific guidance throughout its Sample to Insight workflows. This new product aims to enhance the efficiency and effectiveness of scientific research by integrating advanced AI capabilities. The launch reflects QIAGEN's commitment to leveraging technology for improved scientific outcomes.
Read more →QGENQIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
QIAGEN is set to enhance its drug discovery efforts by utilizing AI-driven technologies, particularly graph-based AI and curated bioinformatics knowledge in collaboration with NVIDIA. This initiative aims to streamline and improve the efficiency of drug discovery processes. The partnership is expected to leverage advanced computational methods to analyze biological data effectively.
Read more →QGENQIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting
QIAGEN has announced the appointment of Dr. Metin Colpan as the Honorary Chairman of the Supervisory Board. This decision is part of the company's ongoing governance renewal efforts. Additionally, QIAGEN plans to propose increased returns at the upcoming 2026 Annual General Meeting.
Read more →QGENQIAGEN plant Einführung eines neuen, vollautomatisierten Sample-to-Insight-Workflows und eines KI-gestützten Tools zur Risikostratifizierung als Weiterentwicklung seines QuantiFERON-Tests zum Nachweis latenter Tuberkulose
QIAGEN announced plans to enhance its QuantiFERON test for latent tuberculosis (TB) with a new automated Sample-to-Insight workflow and an AI-based risk stratification tool. These innovations aim to support high-throughput laboratories in meeting the increasing demand for latent TB screenings. The automated workflow is set to launch by the end of 2027, targeting users of Diasorin's LIAISON systems.
Read more →About Qiagen N.V.
BIOPHARMAWATCH ELITE PLUS
Trade the next QGEN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime